{"id":"NCT04268303","sponsor":"BioXcel Therapeutics Inc","briefTitle":"Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia","officialTitle":"A Phase III Multicenter, Randomized, Double-Blind, Placebo-Controlled Study To Determine Efficacy and Safety of BXCL501 In Agitation Associated With Schizophrenia","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2020-01-24","primaryCompletion":"2020-05-06","completion":"2020-05-06","firstPosted":"2020-02-13","resultsPosted":"2023-06-18","lastUpdate":"2023-06-18"},"enrollment":380,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Agitation","Schizophrenia","Schizo Affective Disorder","Schizoaffective Disorder","Schizophreniform Disorders"],"interventions":[{"type":"DRUG","name":"Sublingual film containing dexmedetomidine (BXCL501)","otherNames":["Dexmedetomidine"]},{"type":"DRUG","name":"Placebo Film","otherNames":["Placebo"]}],"arms":[{"label":"120 Micrograms","type":"EXPERIMENTAL"},{"label":"180 Micrograms","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This is a definitive study to support the safety and efficacy evaluation of BXCL501 for the acute treatment of agitation in schizophrenia. The BXCL501-301 study is designed to characterize the efficacy, safety and tolerability of BXCL501 (sublingual film formulation of DEX, HCl) in agitation associated with schizophrenia, schizoaffective disorder or schizophreniform disorder.","primaryOutcome":{"measure":"Change From Baseline in the Positive and Negative Syndrome Scale- Excited Component (PEC) Total Score","timeFrame":"Baseline and 2 hours","effectByArm":[{"arm":"120 Micrograms","deltaMin":17.5,"sd":2.46},{"arm":"180 Micrograms","deltaMin":17.6,"sd":2.69},{"arm":"Placebo","deltaMin":17.6,"sd":2.26}],"pValues":[{"comp":"OG001 vs OG002","p":"<0.0001"},{"comp":"OG000 vs OG002","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":15,"countries":["United States"]},"refs":{"pmids":["36198061","36002761"],"seeAlso":["https://www.psychiatrist.com/jcp/schizophrenia/sublingual-dexmedetomidine-for-agitation-schizophrenia/"]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":129},"commonTop":["Somnolence","Dry mouth","Headache","Hypotension","Dizziness"]}}